Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled WEgovy Real ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Dec 12 (Reuters) - Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

The company's worst days might be behind it.

How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average ...